-+ 0.00%
-+ 0.00%
-+ 0.00%
Orbis Medicines signs cardiometabolic drug discovery deal with Novo Nordisk worth up to USD 1.4 billion
Share
Listen to the news
Orbis Medicines signs cardiometabolic drug discovery deal with Novo Nordisk worth up to USD 1.4 billion
  • Forbion portfolio company Orbis Medicines signed a multi-target drug discovery partnership with Novo Nordisk valued up to USD 1.4 billion.
  • Deal terms include upfront payment, development milestones, commercial milestones, tiered royalties, and a strategic Novo investment in Orbis.
  • Collaboration targets orally bioavailable macrocycle therapeutics for cardiometabolic diseases using Orbis’ AI-enabled macrocycle discovery platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on September 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending